ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1757

Clinical Use of Belimumab for Systemic Lupus Erythematosus in the Setting of Advanced Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: A Case Series

Matthew Snyder1, Angel Chen1, Sonali Narain2 and Galina Marder2, 1Donald and Barbara Zucker School of Medicine at Hofstra/Northwell at Lenox Hill Hospital Program, New York, NY, 2Northwell Health, Great Neck, NY

Meeting: ACR Convergence 2021

Keywords: belimumab, Renal, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Title: SLE – Treatment Poster (1732–1772)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Belimumab is FDA approved for treatment of SLE and Lupus Nephritis. Patients with an eGFR < 30 ml/min/1.73m2 were excluded from clinical trials, thus limiting data on its use in SLE patients with advanced chronic kidney disease (CKD) and end-stage renal disease (ESRD). We describe a case series on the safety and utility of belimumab in these patients.

Methods: We conducted a retrospective chart review of patients >18 years old, at Northwell Health, with SLE and CKD stage 4 or worse (sustained eGFR < 30) or ESRD on hemodialysis/peritoneal dialysis. Patients treated with both intravenous and subcutaneous belimumab from 2010 to 2020 were included. We excluded patients with a transient eGFR < 30. Clinical and laboratory data and concomitant immunosuppressive medications were collected in 3-month intervals from 12 months before belimumab initiation to the last time point of belimumab use. The primary endpoint was safety defined by absence of events of interest, including allergic reactions, infections (viral, bacterial, and opportunistic), depression, suicide, and death. As secondary endpoints, we compared median SLEDAI change, serologic parameters, prednisone dose equivalent, and number of flares as determined by SLEDAI SELENA flare index for 12 months before belimumab use and while on belimumab. The only time points that had all data available were analyzed for efficacy.

Results: Of 353 patients, we identified six patients with sustained eGFR < 30 or requiring dialysis on belimumab therapy. Baseline demographic and clinical characteristics are recorded in Table 1. The average time of belimumab use in this group was 1.5 years (10-42 months). All patients were alive at the time of analysis. Belimumab was discontinued in 4 patients: 2 for renal transplant, 1 for infectious complications, and 1 for worsening of chronic heart failure. A total of 6 infections were recorded over 9 patient years with multiple events seen in 3 patients. Two infectious events were severe and 4 were mild/moderate. Belimumab was resumed after resolution in all but one patient with systemic H. zoster infection. All patients with infections were on concomitant prednisone (4-10mg/day), 1 patient was on thalidomide (100mg/day), and 1 patient was on azathioprine (150mg/day). No depression, suicide, leukopenia, hypogammaglobulinemia were identified (Table 2). Median SLEDAI score decreased by 50% (from 8 to 4) after 6 months of belimumab use. During the same time frame, median dsDNA titers reduced by more than half (from 390 IU/mL to 167 IU/mL), but there was no change in median complement 4 level (from 18.5mg/dL to 21mg/dL). The cumulative prednisone dose decreased by a mean of 3.75 mg/day (from 13.33 mg/day to 9.58 mg/day) comparing time periods before and while on belimumab (Figure 1). Arthralgia was recorded as improved in two-thirds of patients. There was no change in the median number of flares.

Conclusion: Belimumab is relatively safe in SLE patients with advanced CKD and ESRD on dialysis and may be helpful in reducing SLE activity and steroid use in these patients. However, it is important to be cognizant of the risk of infection, especially with concomitant use of other immunosuppressants.


Disclosures: M. Snyder, None; A. Chen, None; S. Narain, None; G. Marder, GSK, 5.

To cite this abstract in AMA style:

Snyder M, Chen A, Narain S, Marder G. Clinical Use of Belimumab for Systemic Lupus Erythematosus in the Setting of Advanced Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: A Case Series [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/clinical-use-of-belimumab-for-systemic-lupus-erythematosus-in-the-setting-of-advanced-chronic-kidney-disease-and-end-stage-renal-disease-on-dialysis-a-case-series/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-use-of-belimumab-for-systemic-lupus-erythematosus-in-the-setting-of-advanced-chronic-kidney-disease-and-end-stage-renal-disease-on-dialysis-a-case-series/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology